Related Experiment Video

Updated: Jun 13, 2026

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Development of phosphoinositide-3 kinase pathway inhibitors for advanced cancer

James M Cleary1, Geoffrey I Shapiro

  • 1Department of Medical Oncology, Early Drug Development Center, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA, 02115, USA.

Current Oncology Reports
|April 29, 2010
PubMed

Insights

The phosphoinositide-3 kinase (PI3K) pathway is crucial for cancer growth and resistance to treatment. Inhibitors targeting this pathway show promise in clinical trials and combination therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The phosphoinositide-3 kinase (PI3K) pathway is integral to cancer cell proliferation and survival.
  • PI3K pathway activation is implicated in various human cancers through genetic alterations and receptor tyrosine kinase activity.
  • This pathway also contributes to acquired resistance against chemotherapy and targeted therapies.

Purpose of the Study:

  • To review preclinical and clinical data on PI3K pathway inhibitors.
  • To evaluate the potential of PI3K inhibitors as a novel class of anticancer agents.
  • To explore the rationale for combining PI3K inhibitors with other anticancer treatments.

Main Methods:

  • Review of preclinical studies on PI3K pathway inhibitors.
  • Analysis of clinical trial data for PI3K inhibitors.
  • Examination of genetic alterations leading to PI3K pathway activation in cancer.

Main Results:

  • PI3K pathway inhibitors have demonstrated efficacy in preclinical cancer models.
  • Phase 1 clinical trials indicate the promise of this novel drug class.
  • PI3K pathway activation is a common mechanism in cancer and resistance development.

Conclusions:

  • PI3K pathway inhibitors represent a significant advancement in cancer therapy.
  • Further clinical investigation and combination strategies are warranted.
  • Targeting the PI3K pathway offers a promising approach for overcoming cancer resistance.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...